A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients With Uncontrolled Blood Pressure

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04714320

Acronym

ASTRAAS

Enrollment

160

Registered

2021-01-19

Start date

2021-04-28

Completion date

2022-10-03

Last updated

2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Hypertensive, AGT, Angiotensinogen, Blood Pressure

Brief summary

The purpose of this study was to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx on ambulatory blood pressure, seated automated office SBP, seated automated office diastolic blood pressure (DBP), and plasma angiotensinogen (AGT) at each scheduled visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.

Detailed description

This was a phase 2, double-blind, randomized, placebo-controlled study in up to 160 participants. Participants were randomized in a 2:1 ratio and received a once-weekly subcutaneous (SC) treatment with either IONIS-AGT-LRx or matching placebo. The length of participation in the study was approximately 31 weeks, which included an up to 6-week screening period, a 12-week treatment period, and a 13-week post-treatment period.

Interventions

DRUGPlacebo

ISIS 757456 matching placebo administered by SC injection.

DRUGIONIS-AGT-LRx

IONIS-AGT-LRx administered by SC injection.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Males or females aged 18-80 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent * Females: must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal * Males must be abstinent, surgically sterile or if engaged in sexual relations with a woman of childbearing potential (WOCBP), a highly effective contraceptive method must be used * Body mass index (BMI) ≤ 45.0 kilograms per square meter (kg/m\^2) * At screening, the participant must have been on a stable, maximally tolerated regimen (per Investigator judgement) of 3 or more antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study. The combination of antihypertensive medications must be in the following categories: a) angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), b) beta blocker: c) calcium channel blocker d) diuretic, e) alpha-1 blocker f) centrally acting sympatholytic agent or g) direct acting vasodilators (e.g. hydralazine)

Exclusion criteria

* Clinically significant abnormalities in screening laboratory results, medical history according to Investigator judgment * History of secondary hypertension (HTN) including, but not limited to any of the following: renovascular HTN (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced HTN * The use of the following at time of screening and during the course of the study: * Other medications for the treatment of HTN (e.g., minoxidil, diazoxide, renin inhibitors) * Medications that may cause hyperkalemia unless on a stable dose at least 1 month prior to the screening visit and no known history of hyperkalemia per Investigator judgement * Use of oral anticoagulants, unless stable for 4 weeks prior to the first dose of study drug and regular monitoring must be performed per clinical practice during the study unless the participant is receiving vitamin K agonists. If the participant is receiving vitamin K antagonists (e.g., warfarin) international normalized ratio (INR) should be in therapeutic range, as established by the Investigator, for 4 weeks prior to the first dose * Chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase 2 (COX-2) inhibitors (except aspirin for cardiovascular disease provided the total daily dose does not exceed 325 mg) * History of bleeding diathesis, coagulopathy, immune thrombocytopenic purpura (ITP), thrombotic cytopenic purpura (TTP), or any qualitative or quantitative platelet defect * Unstable/underlying known cardiovascular disease defined as: * Any history of congestive heart failure (New York Heart Association \[NYHA\] Class III-IV) * Any history of previous myocardial infarction, coronary revascularization, unstable or stable angina pectoris ˂ 1 year prior to screening * Any hemodynamically unstable atrial or ventricular arrhythmias * Significant uncorrected valvular heart disease * Any history of stroke or transient ischemic attack \< 1 year prior to screening * A cardiac valve repair, cardiac device implantation, and/or a hospitalization for heart failure within 3 months of screening * Participant works nighttime shifts (e.g., 11 PM to 7 AM)

Design outcomes

Primary

Measure	Time frame
Change From Baseline in Seated Automated Office SBP to Day 85	Baseline to Day 85

Secondary

Measure	Time frame
Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169
Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169
Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Baseline, Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169
Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Baseline, Day 85
Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169
Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169
Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169
Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Baseline, Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169

Countries

Canada, United States

Participant flow

Recruitment details

Participants took part in the study at investigative sites in the US and Canada from 28 April 2021 to 03 October 2022.

Pre-assignment details

Participants with uncontrolled hypertension who were on ≥ 3 antihypertensive medications were enrolled and randomized to receive either ISIS 757456 80 mg, ISIS 757456 120 mg or ISIS 757456 matched placebo for a 12-week treatment period.

Participants by arm

Arm	Count
Pooled Placebo Participants received ISIS 757456 matching placebo, SC injection, once weekly for 12 weeks.	53
IONIS-AGT-LRx 80 mg Participants received ISIS 757456 80mg, SC injection, once weekly for 12 weeks.	54
IONIS-AGT-LRx 120 mg Participants received ISIS 757456 120 mg, SC injection, once weekly for 12 weeks.	53
Total	160

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Adverse Event or Serious Adverse Event (SAE)	0	0	1
Overall Study	Reason Not Specified	1	3	3
Overall Study	Voluntary Withdrawal	4	1	2

Baseline characteristics

Characteristic	Pooled Placebo	IONIS-AGT-LRx 80 mg	IONIS-AGT-LRx 120 mg	Total
Age, Continuous	63.1 years STANDARD_DEVIATION 8.29	64.0 years STANDARD_DEVIATION 7.47	61.3 years STANDARD_DEVIATION 9.17	62.8 years STANDARD_DEVIATION 8.36
Ethnicity (NIH/OMB) Hispanic or Latino	20 Participants	15 Participants	14 Participants	49 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	33 Participants	39 Participants	39 Participants	111 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Race Asian	0 Participants	1 Participants	2 Participants	3 Participants
Race/Ethnicity, Customized Race Black	16 Participants	20 Participants	21 Participants	57 Participants
Race/Ethnicity, Customized Race Multiple Races	0 Participants	3 Participants	0 Participants	3 Participants
Race/Ethnicity, Customized Race Native Hawaiian or Other Pacific Islander	1 Participants	0 Participants	1 Participants	2 Participants
Race/Ethnicity, Customized Race Other Race	1 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Race White	35 Participants	30 Participants	29 Participants	94 Participants
Seated Automated Office Diastolic Blood Pressure (DBP) -FAS	82.1 mmHg STANDARD_DEVIATION 8.91	81.5 mmHg STANDARD_DEVIATION 10.2	82.8 mmHg STANDARD_DEVIATION 10.32	82.1 mmHg STANDARD_DEVIATION 9.78
Seated Automated Office Diastolic Blood Pressure (DBP)- PPS	82.5 mmHg STANDARD_DEVIATION 8.5	80.6 mmHg STANDARD_DEVIATION 10.18	81.7 mmHg STANDARD_DEVIATION 10.48	81.6 mmHg STANDARD_DEVIATION 9.72
Seated Automated Office Systolic Blood Pressure (SBP) -FAS	147.6 mmHg STANDARD_DEVIATION 13.92	143.6 mmHg STANDARD_DEVIATION 10.04	144.1 mmHg STANDARD_DEVIATION 11.42	145.1 mmHg STANDARD_DEVIATION 11.95
Seated Automated Office Systolic Blood Pressure (SBP)- PPS	148.8 millimeters of mercury (mmHg) STANDARD_DEVIATION 12.51	143.3 millimeters of mercury (mmHg) STANDARD_DEVIATION 10.29	144.0 millimeters of mercury (mmHg) STANDARD_DEVIATION 11.35	145.3 millimeters of mercury (mmHg) STANDARD_DEVIATION 11.59
Sex: Female, Male Female	33 Participants	32 Participants	32 Participants	97 Participants
Sex: Female, Male Male	20 Participants	22 Participants	21 Participants	63 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 53	0 / 54	1 / 53
other Total, other adverse events	9 / 53	18 / 54	14 / 53
serious Total, serious adverse events	1 / 53	2 / 54	1 / 53

Outcome results

Primary

Change From Baseline in Seated Automated Office SBP to Day 85

Time frame: Baseline to Day 85

Population: PPS included all FAS participants who received at least 10 of the 12 doses of study drug, did not alter antihypertensive medications during the treatment period and prior to Day 85, and had no significant protocol deviations that would have been expected to affect efficacy assessment.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Day 85	-9 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Day 85	-13 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Day 85	-9 mmHg

Comparison: Change From Baseline in Seated Automated Office SBP to Day 85p-value: =0.135ANCOVA

Comparison: Change From Baseline in Seated Automated Office SBP to Day 85p-value: =0.867ANCOVA

Secondary

Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit

Time frame: Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169

Population: PPS included all FAS participants who received at least 10 of the 12 doses of study drug, did not alter antihypertensive medications during the Treatment Period and prior to Study Day 85, and have no significant protocol deviations that would be expected to affect efficacy assessment. 'Number analyzed' indicates the number of participants with data available for analysis at the specified time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 106	756.89 nmol/L	Standard Deviation 212.891
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 120	746.63 nmol/L	Standard Deviation 190.789
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 148	753.35 nmol/L	Standard Deviation 186.906
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 43	837.24 nmol/L	Standard Deviation 251.61
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 169	797.92 nmol/L	Standard Deviation 238.442
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 15	878.36 nmol/L	Standard Deviation 239.895
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 57	848.45 nmol/L	Standard Deviation 256.088
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 71	790.50 nmol/L	Standard Deviation 256.568
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 85	793.77 nmol/L	Standard Deviation 202.796
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 92	748.11 nmol/L	Standard Deviation 204.231
Pooled Placebo	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 29	836.74 nmol/L	Standard Deviation 228.202
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 71	308.99 nmol/L	Standard Deviation 174.893
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 29	388.61 nmol/L	Standard Deviation 193.723
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 92	330.68 nmol/L	Standard Deviation 176.868
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 120	531.33 nmol/L	Standard Deviation 203.681
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 85	328.28 nmol/L	Standard Deviation 199.364
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 57	303.03 nmol/L	Standard Deviation 168.53
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 148	658.33 nmol/L	Standard Deviation 248.413
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 15	575.68 nmol/L	Standard Deviation 248.708
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 106	429.04 nmol/L	Standard Deviation 175.316
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 169	676.60 nmol/L	Standard Deviation 236.881
IONIS-AGT-LRx 80 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 43	319.86 nmol/L	Standard Deviation 180.741
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 169	700.48 nmol/L	Standard Deviation 195.702
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 15	446.29 nmol/L	Standard Deviation 189.521
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 29	293.27 nmol/L	Standard Deviation 129.051
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 43	239.02 nmol/L	Standard Deviation 133.633
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 57	293.12 nmol/L	Standard Deviation 157.651
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 85	321.71 nmol/L	Standard Deviation 176.356
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 92	317.93 nmol/L	Standard Deviation 159.204
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 106	443.95 nmol/L	Standard Deviation 196.226
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 120	562.27 nmol/L	Standard Deviation 202.035
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 148	662.13 nmol/L	Standard Deviation 130.207
IONIS-AGT-LRx 120 mg	Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit	At Day 71	308.86 nmol/L	Standard Deviation 156.533

Secondary

Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit

Time frame: Baseline, Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 71	-47.31 nmol/L	Standard Deviation 239.488
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Baseline	833.42 nmol/L	Standard Deviation 196.561
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 15	44.94 nmol/L	Standard Deviation 137.033
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 29	3.31 nmol/L	Standard Deviation 132.768
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 43	8.15 nmol/L	Standard Deviation 152.008
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 57	15.03 nmol/L	Standard Deviation 182.246
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 85	-39.65 nmol/L	Standard Deviation 171.289
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 92	-73.33 nmol/L	Standard Deviation 153.744
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 106	-57.84 nmol/L	Standard Deviation 169.818
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 120	-64.61 nmol/L	Standard Deviation 131.455
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 148	-62.29 nmol/L	Standard Deviation 153.117
Pooled Placebo	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 169	-18.31 nmol/L	Standard Deviation 170.377
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 169	-189.48 nmol/L	Standard Deviation 260.868
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 71	-578.49 nmol/L	Standard Deviation 276.95
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 85	-544.60 nmol/L	Standard Deviation 314.195
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 106	-449.05 nmol/L	Standard Deviation 288.731
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Baseline	877.70 nmol/L	Standard Deviation 290.487
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 57	-577.72 nmol/L	Standard Deviation 282.528
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 148	-225.14 nmol/L	Standard Deviation 233.595
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 15	-303.67 nmol/L	Standard Deviation 187.426
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 92	-542.20 nmol/L	Standard Deviation 281.935
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 43	-557.84 nmol/L	Standard Deviation 267.373
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 29	-489.09 nmol/L	Standard Deviation 260.294
IONIS-AGT-LRx 80 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 120	-341.33 nmol/L	Standard Deviation 259.403
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 29	-543.33 nmol/L	Standard Deviation 211.294
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 43	-544.34 nmol/L	Standard Deviation 227.409
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 120	-282.34 nmol/L	Standard Deviation 182.477
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 57	-542.84 nmol/L	Standard Deviation 223.631
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 85	-517.42 nmol/L	Standard Deviation 230.73
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 92	-523.31 nmol/L	Standard Deviation 219.037
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 148	-165.06 nmol/L	Standard Deviation 139.585
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 71	-522.65 nmol/L	Standard Deviation 216.465
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Baseline	836.60 nmol/L	Standard Deviation 189.204
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 106	-395.60 nmol/L	Standard Deviation 218.864
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 15	-390.31 nmol/L	Standard Deviation 189.039
IONIS-AGT-LRx 120 mg	Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit	Change From Baseline at Day 169	-129.72 nmol/L	Standard Deviation 146.013

Comparison: Change from Baseline at Day 106p-value: <0.001Van Elteren

Comparison: Change From Baseline at Day 15p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 29p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 43p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 57p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 71p-value: <0.001Van Elteren

Comparison: Change from Baseline at Day 85p-value: <0.001Van Elteren

Comparison: Change from Baseline at Day 92p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 106p-value: <0.001Van Elteren

Comparison: Change from Baseline at Day 120p-value: <0.001ANCOVA

Comparison: Change from Baseline at Day 148p-value: <0.001Van Elteren

Comparison: Change from Baseline at Day 148p-value: =0.002Van Elteren

Comparison: Change from Baseline at Day 169p-value: <0.001Van Elteren

Comparison: Change from Baseline at Day 169p-value: =0.002Van Elteren

Secondary

Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit

Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169

Population: PPS included all FAS participants who received at least 10 of 12 doses of study drug, did not alter antihypertensive medications during treatment period and prior to Day 85,and had no significant protocol deviations that would have been expected to affect efficacy assessment. 'Number analyzed' is the number of participants with data available for analysis at the specified timepoint

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-5.20 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-4.72 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-4.78 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-5.07 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-8.06 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-5.50 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-7.83 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-7.52 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-5.93 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-7.59 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-4.07 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-5.61 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-4.87 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-4.67 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-6.13 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-6.37 mmHg
Pooled Placebo	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-6.05 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-6.11 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-3.47 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-4.70 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-5.62 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-6.72 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-6.32 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-6.87 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-5.99 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-7.90 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-5.73 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-5.36 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-6.78 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-5.82 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-5.94 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-3.50 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-4.80 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-5.34 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-4.38 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-6.13 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-3.90 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-1.54 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-4.87 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-4.84 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-3.86 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-4.85 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-4.31 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-4.25 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-5.26 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-4.68 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-6.46 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-6.26 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-3.29 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-5.87 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-5.42 mmHg

Comparison: Change from Baseline at Day 8p-value: =0.378ANCOVA

Comparison: Change from Baseline at Day 8p-value: =0.648ANCOVA

Comparison: Change from Baseline at Day 15p-value: =0.961ANCOVA

Comparison: Change from Baseline at Day 15p-value: =0.817ANCOVA

Comparison: Change from Baseline at Day 22p-value: =0.823ANCOVA

Comparison: Change from Baseline at Day 22p-value: =0.362ANCOVA

Comparison: Change from Baseline at Day 29p-value: =0.66ANCOVA

Comparison: Change from Baseline at Day 29p-value: =0.539ANCOVA

Comparison: Change from Baseline at Day 36p-value: =0.43ANCOVA

Comparison: Change from Baseline at Day 36p-value: =0.594ANCOVA

Comparison: Change from Baseline at Day 43p-value: =0.783ANCOVA

Comparison: Change from Baseline at Day 43p-value: =0.599ANCOVA

Comparison: Change from Baseline at Day 50p-value: =0.454ANCOVA

Comparison: Change from Baseline at Day 50p-value: =0.394ANCOVA

Comparison: Change from Baseline at Day 57p-value: =0.93ANCOVA

Comparison: Change from Baseline at Day 57p-value: =0.313ANCOVA

Comparison: Change from Baseline at Day 64p-value: =0.276ANCOVA

Comparison: Change from Baseline at Day 64p-value: =0.168ANCOVA

Comparison: Change from Baseline at Day 71p-value: =0.199ANCOVA

Comparison: Change from Baseline at Day 71p-value: =0.506ANCOVA

Comparison: Change from Baseline at Day 78p-value: =0.32ANCOVA

Comparison: Change from Baseline at Day 78p-value: =0.25ANCOVA

Comparison: Change from Baseline at Day 85p-value: =0.373ANCOVA

Comparison: Change from Baseline at Day 85p-value: =0.597ANCOVA

Comparison: Change from Baseline at Day 92p-value: =0.867ANCOVA

Comparison: Change from Baseline at Day 92p-value: =0.5ANCOVA

Comparison: Change from Baseline at Day 106p-value: =0.863ANCOVA

Comparison: Change from Baseline at Day 106p-value: =0.681ANCOVA

Comparison: Change from Baseline at Day 120p-value: =0.262ANCOVA

Comparison: Change from Baseline at Day 120p-value: =0.645ANCOVA

Comparison: Change from Baseline at Day 148p-value: =0.947ANCOVA

Comparison: Change from Baseline at Day 148p-value: =0.665ANCOVA

Comparison: Change from Baseline at Day 169p-value: =0.498ANCOVA

Comparison: Change from Baseline at Day 169p-value: =0.173ANCOVA

Secondary

Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit

Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169

Population: PPS included all FAS participants who received at least 10 of 12 doses of study drug did not alter antihypertensive medications during treatment period \& prior to Day 85 have no significant protocol deviations that would be expected to affect efficacy assessment. 'Number analyzed' indicates number of participants with data available for analysis at specified time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-9.64 mmHg	Standard Deviation 16.346
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-10.93 mmHg	Standard Deviation 12.25
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-7.38 mmHg	Standard Deviation 14.967
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-14.19 mmHg	Standard Deviation 11.827
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-10.13 mmHg	Standard Deviation 13.844
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-9.31 mmHg	Standard Deviation 11.853
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-12.26 mmHg	Standard Deviation 14.671
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-13.31 mmHg	Standard Deviation 13.019
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-9.36 mmHg	Standard Deviation 13.24
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-9.50 mmHg	Standard Deviation 15.725
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-7.98 mmHg	Standard Deviation 13.973
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-12.14 mmHg	Standard Deviation 13.258
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-9.49 mmHg	Standard Deviation 16.385
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-9.23 mmHg	Standard Deviation 13.336
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-11.76 mmHg	Standard Deviation 18.127
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-11.48 mmHg	Standard Deviation 15.953
Pooled Placebo	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-9.07 mmHg	Standard Deviation 13.65
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-9.37 mmHg	Standard Deviation 16.435
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-5.87 mmHg	Standard Deviation 12.427
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-7.73 mmHg	Standard Deviation 13.768
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-7.84 mmHg	Standard Deviation 16.1
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-9.13 mmHg	Standard Deviation 14.258
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-11.73 mmHg	Standard Deviation 15.193
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-9.64 mmHg	Standard Deviation 17.112
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-9.89 mmHg	Standard Deviation 14.257
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-7.70 mmHg	Standard Deviation 14.305
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-8.35 mmHg	Standard Deviation 15.426
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-11.57 mmHg	Standard Deviation 13.971
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-10.93 mmHg	Standard Deviation 15.319
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-7.57 mmHg	Standard Deviation 15.855
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-8.57 mmHg	Standard Deviation 16.476
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-5.14 mmHg	Standard Deviation 15.514
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-6.76 mmHg	Standard Deviation 15.637
IONIS-AGT-LRx 80 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-8.76 mmHg	Standard Deviation 16.798
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 8	-4.78 mmHg	Standard Deviation 13.306
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 85	-6.98 mmHg	Standard Deviation 15.995
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 29	-6.91 mmHg	Standard Deviation 12.096
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 169	-2.02 mmHg	Standard Deviation 17.468
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 92	-6.57 mmHg	Standard Deviation 13.11
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 22	-6.80 mmHg	Standard Deviation 13.881
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 148	-4.30 mmHg	Standard Deviation 14.393
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 106	-6.61 mmHg	Standard Deviation 16.158
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 15	-4.11 mmHg	Standard Deviation 11.443
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 64	-8.19 mmHg	Standard Deviation 15.241
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 57	-7.47 mmHg	Standard Deviation 18.194
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 36	-6.40 mmHg	Standard Deviation 14.318
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 71	-5.71 mmHg	Standard Deviation 16.045
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 50	-6.13 mmHg	Standard Deviation 16.453
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 120	-5.14 mmHg	Standard Deviation 15.02
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 78	-8.22 mmHg	Standard Deviation 14.734
IONIS-AGT-LRx 120 mg	Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit	Change from Baseline at Day 43	-7.24 mmHg	Standard Deviation 16.563

Comparison: Change from Baseline at Day 8p-value: =0.853ANCOVA

Comparison: Change from Baseline at Day 8p-value: =0.542ANCOVA

Comparison: Change from Baseline at Day 15p-value: =0.43ANCOVA

Comparison: Change from Baseline at Day 15p-value: =0.587ANCOVA

Comparison: Change from Baseline at Day 22p-value: =0.91ANCOVA

Comparison: Change from Baseline at Day 22p-value: =0.846ANCOVA

Comparison: Change from Baseline at Day 29p-value: 0.634ANCOVA

Comparison: Change from Baseline at Day 29p-value: =0.767ANCOVA

Comparison: Change from Baseline at Day 36p-value: =0.399ANCOVA

Comparison: Change from Baseline at Day 36p-value: =0.323ANCOVA

Comparison: Change from Baseline at Day 43p-value: =0.115ANCOVA

Comparison: Change from Baseline at Day 43p-value: =0.982ANCOVA

Comparison: Change from Baseline at Day 50p-value: =0.859ANCOVA

Comparison: Change from Baseline at Day 50p-value: =0.344ANCOVA

Comparison: Change from Baseline at Day 57p-value: =0.633ANCOVA

Comparison: Change from Baseline at Day 57p-value: =0.889ANCOVA

Comparison: Change from Baseline at Day 64p-value: =0.241ANCOVA

Comparison: Change from Baseline at Day 64p-value: =0.367ANCOVA

Comparison: Change from Baseline at Day 71p-value: =0.716ANCOVA

Comparison: Change from Baseline at Day 71p-value: =0.21ANCOVA

Comparison: Change from Baseline at Day 78p-value: =0.363ANCOVA

Comparison: Change from Baseline at Day 78p-value: =0.193ANCOVA

Comparison: Change from Baseline at Day 85p-value: =0.135ANCOVA

Comparison: Change from Baseline at Day 85p-value: =0.867ANCOVA

Comparison: Change from Baseline at Day 92p-value: =0.761ANCOVA

Comparison: Change from Baseline at Day 92p-value: =0.618ANCOVA

Comparison: Change from Baseline at Day 106p-value: =0.363Van Elteren

Comparison: Change from Baseline at Day 106p-value: =0.125Van Elteren

Comparison: Change from Baseline at Day 120p-value: =0.435ANCOVA

Comparison: Change from Baseline at Day 120p-value: =0.413ANCOVA

Comparison: Change from Baseline at Day 148p-value: =0.658ANCOVA

Comparison: Change from Baseline at Day 148p-value: =0.275ANCOVA

Comparison: Change from Baseline at Day 169p-value: =0.578ANCOVA

Comparison: Change from Baseline at Day 169p-value: =0.114ANCOVA

Secondary

Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)

Time frame: Baseline, Day 85

Population: PPS included all FAS participants who received at least 10 of the 12 doses of study drug, did not alter antihypertensive medications during the Treatment Period and prior to Study Day 85, and have no significant protocol deviations that would be expected to affect efficacy assessment. 'Overall number of participants analyzed' indicates the number of participants with data available for the analysis of this outcome measure.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Pooled Placebo	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean SBP at Day 85	-1.362 mmHg
Pooled Placebo	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean DBP at Day 85	-1.667 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean DBP at Day 85	-4.406 mmHg
IONIS-AGT-LRx 80 mg	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean SBP at Day 85	-5.675 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean DBP at Day 85	-2.792 mmHg
IONIS-AGT-LRx 120 mg	Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)	Change from Baseline in 24-hour Mean SBP at Day 85	-0.862 mmHg

Comparison: Change from Baseline in 24-hour Mean SBP at Day 85p-value: =0.094ANCOVA

Comparison: Change from Baseline in 24-hour Mean SBP at Day 85p-value: =0.842ANCOVA

Comparison: Change From Baseline in 24-hour Mean DBP at Day 85p-value: =0.066ANCOVA

Comparison: Change From Baseline in 24-hour Mean DBP at Day 85p-value: =0.442ANCOVA

Secondary

Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit

Time frame: Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169

Population: PPS analysis set was used. Participants with SBP ≤ 140 mmHg at baseline were excluded from this analysis. 'Overall number of participants analyzed' indicates the number of participants with data available for the analysis of this outcome measure. 'Number analyzed' indicates number of participants with data available for analysis at specified time point.

Arm	Measure	Group	Value (NUMBER)
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 8	37.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 120	51.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 169	86.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 169	50.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 106	86.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 148	82.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 8	81.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 85	40.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 120	81.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 15	78.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 29	46.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 92	82.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 22	87.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 169	50.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 85	81.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 29	81.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 78	56.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 78	93.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 36	83.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 36	48.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 71	93.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 43	90.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 120	51.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 64	96.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 50	87.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 71	48.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 57	90.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 43	40.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 29	46.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64	59.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 50	58.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 148	44.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 8	37.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 57	46.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 64	59.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 57	46.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50	58.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 71	48.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 106	55.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 43	40.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 78	56.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 15	31.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 36	45.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 85	40.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 148	37.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 22	28.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 92	55.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 92	51.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 15	28.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 106	55.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 22	31.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 78	46.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 120	48.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 148	48.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 22	65.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 29	50.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 8	38.5 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 15	53.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 22	65.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 29	53.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 36	60.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 43	69.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 50	57.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 57	53.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 64	36.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 71	48.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 78	50.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 85	64.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 92	52.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 106	60.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 169	58.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 8	73.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 15	80.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 22	88.5 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 29	88.5 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 36	92.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 43	84.6 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 50	96.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 57	80.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 64	80.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 71	84.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 78	84.6 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 85	88.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 92	88.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 106	95.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 120	72.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 148	80.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 169	83.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 8	34.6 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 15	50.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 36	57.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 43	65.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50	57.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 57	50.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64	36.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 71	44.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 85	60.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 92	48.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 106	60.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 120	44.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 148	44.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 169	54.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 148	95.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 148	34.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 15	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 169	87.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 106	56.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 169	37.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 8	36.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 92	23.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 92	23.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 15	36.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 85	33.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 29	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 78	58.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 8	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 36	52.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 71	56.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 148	34.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 43	41.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 64	68.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 106	52.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50	37.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 57	56.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 22	36.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 57	52.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 43	45.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 120	43.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64	63.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 50	83.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 36	52.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 57	82.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 43	79.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 120	39.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 64	86.4 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 36	92.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 71	52.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 71	92.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 29	80.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 29	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 78	79.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 22	72.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 50	41.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 85	83.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 15	88.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 78	54.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 22	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 106	82.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 8	72.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 92	85.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 90 mmHg at Day 120	95.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg at Day 169	37.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 85	33.3 percentage of participants

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 8p-value: =0.834Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 8p-value: =0.945Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 15p-value: =0.208Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 15p-value: =0.74Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 22p-value: =0.019Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 22p-value: =0.56Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 29p-value: =0.903Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 29p-value: =0.268Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 36p-value: =0.702Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 36p-value: =0.885Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 43p-value: =0.066Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 43p-value: =0.783Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 50p-value: =0.456Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 50p-value: =0.102Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 57p-value: =0.668Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 57p-value: =0.454Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 64p-value: =0.044Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 64p-value: =0.704Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 71p-value: =0.878Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 71p-value: =0.681Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 78p-value: =0.199Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 78p-value: =0.602Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 85p-value: =0.135Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 85p-value: =0.407Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 92p-value: =0.795Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 92p-value: =0.036Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 106p-value: =0.915Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 106p-value: =0.957Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 120p-value: =0.804Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 120p-value: =0.775Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 148p-value: =0.801Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 148p-value: =0.329Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 169p-value: =0.882Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg at Day 169p-value: =0.235Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 8p-value: =0.505Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 8p-value: =0.436Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 15p-value: =0.637Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 15p-value: =0.254Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 22p-value: =0.848Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 22p-value: =0.24Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 29p-value: =0.382Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 29p-value: =0.935Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 36p-value: =0.278Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 36p-value: =0.211Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 43p-value: =0.562Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 43p-value: =0.25Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 50p-value: =0.114Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 50p-value: =0.55Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 57p-value: =0.423Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 57p-value: =0.422Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 64p-value: =0.073Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 64p-value: =0.278Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 71p-value: =0.338Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 71p-value: =0.969Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 78p-value: =0.489Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 78p-value: =0.156Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 85p-value: =0.389Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 85p-value: =0.775Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 92p-value: =0.437Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 92p-value: =0.618Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 106p-value: =0.079Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 106p-value: =0.349Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 120p-value: =0.58Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 120p-value: =0.106Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 148p-value: =0.955Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 148p-value: =0.134Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 169p-value: =0.933Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 90 mmHg at Day 169p-value: =0.502Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 8p-value: =0.653Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 8p-value: =0.816Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 15p-value: =0.184Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 15p-value: =0.765Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 22p-value: =0.009Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 22p-value: =0.578Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 29p-value: =0.725Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 29p-value: =0.287Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 36p-value: =0.705Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 36p-value: =0.975Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 43p-value: =0.118Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 43p-value: =0.959Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50p-value: =0.413Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 50p-value: =0.043Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 57p-value: =0.849Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 57p-value: =0.662Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64p-value: =0.047Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 64p-value: =0.95Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 71p-value: =0.656Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 71p-value: =0.922Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 78p-value: =0.143Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 78p-value: =0.452Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 85p-value: =0.231Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 85p-value: =0.405Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 92p-value: =0.718Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 92p-value: =0.053Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 106p-value: =0.893Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 106p-value: =0.662Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 120p-value: =0.688Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 120p-value: =0.611Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 148p-value: =0.907Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 148p-value: =0.699Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 169p-value: =0.802Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 140 mmHg and DBP ≤ 90 mmHg at Day 169p-value: =0.206Regression, Logistic

Secondary

Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit

Time frame: Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 106, 120, 148, and 169

Population: PPS included all FAS participants who received at least 10 of the 12 doses of study drug, did not alter antihypertensive medications during the Treatment Period and prior to study day 85, and have no significant protocol deviations that would be expected to affect efficacy assessment. 'Number analyzed' indicates the number of participants with data available for analysis at the specified time point.

Arm	Measure	Group	Value (NUMBER)
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 169	55.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 120	28.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 15	48.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 148	53.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 148	31.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 78	37.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 120	64.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 169	30.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 106	61.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 22	59.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 29	28.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 92	66.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 29	60.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 8	53.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 85	60.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 36	56.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 71	30.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 78	67.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 43	57.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 36	36.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 120	25.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 71	58.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 57	66.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64	33.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 64	60.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 43	28.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 50	63.6 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 57	22.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 50	27.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 106	31.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 50	25.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 57	24.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 15	20.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 43	24.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 64	40.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 8	20.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 36	27.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 71	30.2 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 169	27.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 29	24.4 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 78	41.9 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 92	38.1 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 22	27.3 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 85	26.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 148	26.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 15	20.0 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 92	40.5 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 85	26.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 8	17.8 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 106	35.7 percentage of participants
Pooled Placebo	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 22	27.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 71	44.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 8	64.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 15	66.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 8	37.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 15	35.6 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 22	31.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 29	44.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 36	43.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 43	46.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 50	44.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 57	43.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 64	31.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 169	42.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 78	44.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 85	50.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 92	34.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 106	52.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 120	34.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 148	33.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 22	64.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 29	68.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 36	75.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 43	71.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 50	66.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 57	68.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 64	68.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 71	58.1 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 78	69.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 85	75.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 92	70.5 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 106	66.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 120	63.6 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 148	61.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 169	66.7 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 8	33.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 15	33.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 22	24.4 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 29	40.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 36	37.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 43	37.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 50	37.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 57	40.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64	25.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 71	34.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 78	37.2 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 85	40.9 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 92	27.3 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 106	40.5 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 120	31.8 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 148	31.0 percentage of participants
IONIS-AGT-LRx 80 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 169	38.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 92	33.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 8	60.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 8	26.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 85	37.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 85	31.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 15	17.4 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 78	37.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 8	30.4 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 22	30.4 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 71	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 169	27.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 29	34.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 64	34.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 92	28.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 36	35.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 57	39.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 106	59.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 43	35.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 50	40.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 148	23.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 50	28.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 43	44.4 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 106	29.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 57	30.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 36	48.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 57	65.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 43	60.0 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 64	62.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 50	53.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64	25.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 71	62.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 36	55.6 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 29	43.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 78	66.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 29	65.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 169	34.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 85	66.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 22	58.7 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 71	31.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 92	64.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 15	56.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 22	34.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 148	27.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 120	23.3 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 120	60.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 120	30.2 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 78	37.8 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 148	60.5 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 106	40.9 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With SBP ≤ 130 mmHg at Day 15	26.1 percentage of participants
IONIS-AGT-LRx 120 mg	Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit	Percentage of Participants With DBP ≤ 80 mmHg at Day 169	48.8 percentage of participants

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 8p-value: =0.28Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 8p-value: =0.648Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 15p-value: =0.416Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 15p-value: =0.9Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 22p-value: =0.627Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 22p-value: =0.921Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 29p-value: =0.464Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 29p-value: =0.458Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 36p-value: =0.779Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 36p-value: =0.629Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 43p-value: =0.242Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 43p-value: =0.29Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 50p-value: =0.349Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 50p-value: =0.532Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 57p-value: =0.205Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 57p-value: =0.368Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 64p-value: =0.084Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 64p-value: =0.179Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 71p-value: =0.584Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 71p-value: =0.762Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 78p-value: =0.675Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 78p-value: =0.166Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 85p-value: =0.09Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 85p-value: =0.488Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 92p-value: =0.218Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 92p-value: =0.232Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 106p-value: =0.421Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 106p-value: =0.815Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 120p-value: =0.711Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 120p-value: =0.514Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 148p-value: =0.479Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 148p-value: =0.292Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 169p-value: =0.528Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg at Day 169p-value: =0.946Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 8p-value: =0.552Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 8p-value: =0.598Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 15p-value: =0.184Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 15p-value: =0.614Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 22p-value: =0.933Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 22p-value: =0.803Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 29p-value: =0.686Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 29p-value: =0.752Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 36p-value: =0.106Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 36p-value: =0.779Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 43p-value: =0.323Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 43p-value: =0.991Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 50p-value: =0.973Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 50p-value: =0.23Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 57p-value: =0.792Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 57p-value: =0.744Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 64p-value: =0.925Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 64p-value: =0.991Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 71p-value: =0.53Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 71p-value: =0.849Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 78p-value: =0.953Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 78p-value: =0.884Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 85p-value: =0.23Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 85p-value: =0.589Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 92p-value: =0.919Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 92p-value: =0.753Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 106p-value: =0.747Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 106p-value: =0.764Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 120p-value: =0.527Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 120p-value: =0.639Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 148p-value: =0.744Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 148p-value: =0.539Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 169p-value: =0.417Regression, Logistic

Comparison: Seated Automated Office DBP ≤ 80 mmHg at Day 169p-value: =0.466Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 8p-value: =0.38Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 8p-value: =0.73Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 15p-value: =0.595Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 15p-value: =0.279Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 22p-value: =0.196Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 22p-value: =0.728Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 29p-value: =0.453Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 29p-value: =0.681Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 36p-value: =0.837Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 36p-value: =0.863Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 43p-value: =0.504Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 43p-value: =0.531Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 50p-value: =0.6Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 50p-value: =0.83Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 57p-value: =0.209Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 57p-value: =0.809Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64p-value: =0.045Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 64p-value: =0.104Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 71p-value: =0.69Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 71p-value: =0.59Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 78p-value: =0.538Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 78p-value: =0.407Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 85p-value: =0.398Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 85p-value: =0.93Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 92p-value: =0.111Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 92p-value: =0.196Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 106p-value: =0.816Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 106p-value: =0.473Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 120p-value: =0.615Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 120p-value: =0.214Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 148p-value: =0.575Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 148p-value: =0.276Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 169p-value: =0.573Regression, Logistic

Comparison: Seated Automated Office SBP ≤ 130 mmHg and DBP ≤ 80 mmHg at Day 169p-value: =0.706Regression, Logistic

Secondary

Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit

Time frame: Baseline, Days 15, 29, 43, 57, 71, 85, 92, 106, 120, 148, and 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 106	-6.3 percent change	Standard Deviation 20.4
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 57	1.6 percent change	Standard Deviation 21.1
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 169	-2.0 percent change	Standard Deviation 19.8
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 92	-8.3 percent change	Standard Deviation 19.5
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 85	-3.3 percent change	Standard Deviation 19.6
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 148	-6.1 percent change	Standard Deviation 20
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 29	0.5 percent change	Standard Deviation 16.7
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 71	-4.8 percent change	Standard Deviation 25.5
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 120	-7.3 percent change	Standard Deviation 14.9
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 43	0.3 percent change	Standard Deviation 18.6
Pooled Placebo	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 15	5.6 percent change	Standard Deviation 16.8
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 57	-63.7 percent change	Standard Deviation 17.9
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 15	-34.3 percent change	Standard Deviation 17.2
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 29	-54.4 percent change	Standard Deviation 18.3
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 43	-62.4 percent change	Standard Deviation 16.5
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 71	-63.3 percent change	Standard Deviation 19.4
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 85	-59.2 percent change	Standard Deviation 27.4
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 92	-60.0 percent change	Standard Deviation 18.7
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 106	-47.6 percent change	Standard Deviation 22.8
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 120	-36.3 percent change	Standard Deviation 20.6
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 148	-22.8 percent change	Standard Deviation 25.4
IONIS-AGT-LRx 80 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 169	-18.3 percent change	Standard Deviation 29.6
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 148	-18.4 percent change	Standard Deviation 15.9
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 106	-46.4 percent change	Standard Deviation 21.9
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 29	-63.6 percent change	Standard Deviation 17.5
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 57	-64.0 percent change	Standard Deviation 18.3
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 120	-33.2 percent change	Standard Deviation 20
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 15	-46.4 percent change	Standard Deviation 18.8
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 85	-60.7 percent change	Standard Deviation 23.1
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 71	-62.0 percent change	Standard Deviation 19
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 169	-15.2 percent change	Standard Deviation 17.3
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 92	-61.4 percent change	Standard Deviation 19
IONIS-AGT-LRx 120 mg	Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit	Percent Change from Baseline at Day 43	-63.2 percent change	Standard Deviation 20.4

Comparison: Percent Change from Baseline at Day 15p-value: <0.001ANCOVA

Comparison: Percent Change from Baseline at Day at 29p-value: <0.001ANCOVA

Comparison: Percent Change from Baseline at Day 43p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 57p-value: <0.001ANCOVA

Comparison: Percent Change from Baseline at Day 71p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 85p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 92p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 106p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 120p-value: <0.001ANCOVA

Comparison: Percent Change from Baseline at Day 148p-value: <0.001ANCOVA

Comparison: Percent Change from Baseline at Day 148p-value: =0.005ANCOVA

Comparison: Percent Change from Baseline at Day 169p-value: <0.001Van Elteren

Comparison: Percent Change from Baseline at Day 169p-value: =0.002Van Elteren

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline in Seated Automated Office SBP to Day 85

Absolute Concentration of Plasma AGT at Each Scheduled, Post-Baseline Visit

Change From Baseline in Plasma AGT to Each Scheduled, Post-Baseline Visit

Change From Baseline in Seated Automated Office DBP to Each Scheduled, Post-Baseline Visit

Change From Baseline in Seated Automated Office SBP to Each Scheduled, Post-Baseline Visit

Change From Baseline to Study Day 85 in 24-hour Mean SBP and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)

Percentage of Participants Who Achieved Seated Automated Office SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and Both at Each Scheduled Post-Baseline Visit

Percentage of Participants Who Achieved Seated Automated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and Both at Each Scheduled Post-Baseline Visit

Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit